Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

被引：0

作者：

Madanat, Yazan F. ^{[1
]}

Sekeres, Mikkael A. ^{[1
]}

Mukherjee, Sudipto ^{[1
]}

Al-Issa, Karam ^{[1
]}

Hirsch, Cassandra M. ^{[2
]}

Gerds, Aaron T. ^{[1
]}

Jha, Babal K. ^{[2
]}

Adema, Vera ^{[2
]}

Advani, Anjali ^{[1
]}

Nagata, Yasunobu ^{[2
]}

Kuzmanovic, Teodora ^{[2
]}

Carraway, Hetty E. ^{[1
]}

Przychodzen, Bartlomiej ^{[2
]}

Maciejewski, Jaroslaw P. ^{[2
]}

Nazha, Aziz ^{[1
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH 44106 USA

[2] Cleveland Clin, Translat Hematol & Oncol, Cleveland, OH 44106 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

MDS; genomics; molecular; leukemia; NGS;

D O I：

10.1016/j.clml.2018.07.172

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-161

引用

页码：S261 / S261

页数：1

共 50 条

[41] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
Freyrie, A.
Reda, G.
Vincenti, D.
Ferla, V.
Orofino, N.
Sciume, M.
Guidotti, F.
Cortelezzi, A.
LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
[42] ACUTE MYELOID LEUKEMIA PROGRESSION IN ARGENTINEAN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.
Enrico, A.
Flores, M. G.
Arbelbide, J.
Kornblihtt, L.
Crisp, R.
Correa, W.
Gonzalez, J.
Bengio, R.
Narbaitz, M.
Pardo, L.
Watman, N.
Bestach, Y.
Rosenhain, M.
Basquiera, A.
Larripa, I.
Iastrebner, M.
Belli, C.
HAEMATOLOGICA, 2015, 100 : 483 - 483
[43] Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes
Kwon, Adelaide
Weinberg, Olga K.
CLINICS IN LABORATORY MEDICINE, 2023, 43 (04) : 657 - 667
[44] Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in Down syndrome: Pathologic aspects
Mast, K.
Taub, J. W.
Alonzo, T.
Mosse, C.
Gamis, A. S.
Mathew, P.
Jones, H.
Hitzler, J.
Head, D. R.
LEUKEMIA RESEARCH, 2013, 37 : S89 - S90
[45] Unlike AML1 (CBFa), CBFb gene is not deregulated through point mutations in acute myeloid leukemia (AML) and in myelodysplastic syndromes (MDS).
Leroy, H
Roumier, C
Grardel, N
Macintyre, E
Lepelley, P
Cosson, A
Fenaux, P
Preudhomme, C
BLOOD, 2001, 98 (11) : 190B - 190B
[46] The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
Snow, Anson
Zeidner, Joshua F.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[47] Erythropoietin (EPO)-dependent transformation of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML).
Bunworasate, U
Arnouk, H
Minderman, H
O'Loughlin, KL
Sait, SNJ
Barcos, M
Baer, MR
BLOOD, 2000, 96 (11) : 259B - 259B
[48] Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following treatment for ovarian cancer
Gupta, B.
Sait, S. N.
Block, A. W.
Ford, L. A.
Moysich, K. B.
Baer, M. R.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[49] CHROMOSOMAL STUDIES IN 24 PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIAS (AML) AND MYELODYSPLASTIC SYNDROMES (MDS)
WEH, HJ
HOFFMANN, R
SUCIU, S
KUSE, R
HOSSFELD, DK
BLUT, 1987, 55 (04): : 236 - 236
[50] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
Seymour, John F.
Silverman, Lewis R.
Doehner, Hartmut
Fenaux, Pierre
Mufti, Ghulam J.
Santini, Valeria
Minden, Mark D.
Stone, Richard M.
Lucy, Lela M.
Songer, Stephen
Dougherty, Donna
Hinkle, Randy
Gambini, Dominique
Beach, C. L.
Dombret, Herve
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →